Analyst Insights

William Blair Maintains Market Perform On Bio-Reference Laboratories Following Strong Third Quarter

In a report issued yesterday, William Blair analyst Amanda Murphy maintained a Market Perform rating on Bio-Reference Laboratories (NASDAQ:BRLI), after reporting third quarter 2014 …

Roth Capital Affirms Buy On Acura Pharmaceuticals Following NIDA Grant

In a research note issued yesterday to investors, Roth Capital analyst Ed Arce affirmed a Buy rating on Acura Pharmaceuticals (ACUR) with a $1.50 price target, after …

Roth Capital Maintains Buy On Tilly’s Shares, Raises PT To $10

In a research report issued today, Roth Capital analyst Dave King maintained a Buy rating on Tilly’s (NYSE:TLYS) and raised his price target …

Roth Capital Maintains Buy On First Cash Financial Services Shares, $62 PT

In a research report issued yesterday, Roth Capital analyst Dave King maintained a Buy rating on First Cash Financial Services (NASDAQ:FCFS) with a …

Sterne Agee Maintains Neutral On Brown Shoe Company Shares

In a research report issued yesterday, Sterne Agee analyst Sam Poser maintained a Neutral rating on Brown Shoe Company (NYSE:BWS). No price target …

Despite Near Term Pain, Our LT Outlook For S&W Remains Largely Unchanged, Says Wedbush

In a research note issued today, Wedbush analyst Rommel Dionisio reiterated coverage with an Outperform rating on Smith & Wesson (NASDAQ:SWHC) shares, but reduced his price target to …

Cantor Fitzgerald Maintains Buy On Yahoo Following Alibaba 2Q:CY14 Results

In a research report released today, Cantor Fitzgerald analyst Youssef Squali reiterated a Buy rating on Yahoo (YHOO) with a $39 price target, following Alibaba’s 2Q:CY14 financial results, which were better than …

Cree: Downside Is Fairly Well Protected Around The $49 Level, Says Wedbush

In a research note released today, Wedbush analyst Craig Irwin maintained an Outperform rating on Cree (NASDAQ:CREE) with a $61 price target, following today’s news that Cree and Lextar Electronics entered …

Roth Capital Reiterates Buy On Nektar Therapeutics; Sees 46% Potential Upside

In a research report issued today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a $21 price target, which represents a potential upside …

Roth Capital Reiterates Buy On Ligand On The Heels Of FDA Approval For Promacta

Ligand Pharma (NASDAQ:LGND) partner GlaxoSmithKline (NYSE:GSK) announced it received FDA approval for the sNDA of Promacta for treatment of cytopenia in patients with …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts